Acquisition / FDA protocolFor those of you concerned about the line of making acquisition, do you really think a guy who is selling everything not bolted down and firing everyone including senior management is going to go out and acquire assets with our current state of affairs? No chance. They are referring to making acquisition after up front funds are in place. Berendt and Olds are not idiots. June is a huge month for shareholders if the FDA trial protocol is in fact set. That means potential suitors can look at this trial and know what the odds are of success. We know that a Papillary trial (most prevalent and most likely) as opposed to In Situ, with 8mm doses immediate post TURBT instillation should produce a CRR result in the 40%-50% range. That is miles above the FDA 20% (likely - if same as first phase 3) threshold. So if the trial protocol comes back as Papillary Post Turbt, you can bet your life (investment) that a partner won't be far behind, with lots of upfront funds to carry us through. If for some reason they want a In Situ trial to run concurrently for a separate cancer then fine. The only thing we don't want is an In Situ trial only, which would make no sense as it is the rarer of the two cancers. beech